Aranesp

TABLE OF CONTENTS

4 Product Profiles
4 Aranesp : Anemia in chronic kidney disease
20 Aranesp : Chemotherapy-induced anemia

LIST OF FIGURES
12 Figure 1: Aranesp for anemia in chronic kidney disease – SWOT analysis
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of Aranesp for anemia in chronic kidney disease
14 Figure 3: Datamonitor Healthcare’s drug assessment summary of Aranesp for anemia in chronic kidney disease
16 Figure 4: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country, 2015–24
27 Figure 5: Aranesp for chemotherapy-induced anemia – SWOT analysis
28 Figure 6: Datamonitor Healthcare’s drug assessment summary of Aranesp in chemotherapy-induced anemia
29 Figure 7: Datamonitor Healthcare’s drug assessment summary of Aranesp in chemotherapy-induced anemia

LIST OF TABLES
4 Table 1: Aranesp drug profile
6 Table 2: Aranesp pivotal trial data in anemia in chronic kidney disease
9 Table 3: Aranesp other late-phase trial data in anemia in chronic kidney disease
17 Table 4: Aranesp sales for anemia in chronic kidney disease across the US, Japan, and five major EU markets, by country ($m), 2015–24
21 Table 5: Aranesp drug profile
23 Table 6: Aranesp pivotal trial data in chemotherapy-induced anemia
25 Table 7: Aranesp late-phase trial data in chemotherapy-induced anemia
26 Table 8: Aranesp ongoing late-phase clinical trial in chemotherapy-induced anemia